Physician profile
William Miller
NPI 1336122563
$1,053.44
in general payments reported to CMS, 2019-2025
12 companies · $20.85 in 2025
The $20.85 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $205 · 2021: $203 · 2022: $210 · 2023: $158 · 2024: $71.82 · 2025: $20.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $204.99 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $156.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $152.27 | 2019-2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $146.65 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $121.03 | 2019-2020 | |
| Pfizer INC. | $79.37 | 2019-2022 | |
| Tris Pharma INC | $69.18 | 2021 | |
| Corium, LLC | $33.65 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $31.56 | 2020-2021 | |
| Sobi, INC | $21.96 | 2023 | |
| Kaleo, INC. | $18.26 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.